In a reprisal of its previous incarnation, NZX-listed cervical cancer screening technology company TruScreen Group has announced its intention to dual list on the ASX.
In a statement to the NZX, the company advised it would also raise $1million to $2m of new equity through a share offer at 7c a
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
